ABBOTT LABORATORIES (ABL.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ABL - US0028241000 - Common Stock
106.42 EUR
-1.34 (-1.24%)
Taking everything into account, ABL scores 6 out of 10 in our fundamental rating. ABL was compared to 66 industry peers in the Health Care Equipment & Supplies industry. ABL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ABL is valied quite expensively at the moment, while it does show a decent growth rate. This makes ABL very considerable for quality investing!
1. Profitability
1.1 Basic Checks
ABL had positive earnings in the past year.
ABL had a positive operating cash flow in the past year.
ABL had positive earnings in each of the past 5 years.
Each year in the past 5 years ABL had a positive operating cash flow.
1.2 Ratios
ABL has a Return On Assets of 16.60%. This is amongst the best in the industry. ABL outperforms 93.94% of its industry peers.
ABL's Return On Equity of 27.43% is amongst the best of the industry. ABL outperforms 95.45% of its industry peers.
ABL's Return On Invested Capital of 9.90% is fine compared to the rest of the industry. ABL outperforms 78.79% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ABL is in line with the industry average of 9.66%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROIC | 9.9% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
1.3 Margins
The Profit Margin of ABL (31.88%) is better than 100.00% of its industry peers.
In the last couple of years the Profit Margin of ABL has grown nicely.
ABL has a better Operating Margin (18.29%) than 77.27% of its industry peers.
In the last couple of years the Operating Margin of ABL has grown nicely.
ABL has a Gross Margin (56.19%) which is in line with its industry peers.
ABL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% |
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ABL is creating some value.
The number of shares outstanding for ABL remains at a similar level compared to 1 year ago.
The number of shares outstanding for ABL has been reduced compared to 5 years ago.
ABL has a better debt/assets ratio than last year.
2.2 Solvency
ABL has an Altman-Z score of 5.76. This indicates that ABL is financially healthy and has little risk of bankruptcy at the moment.
ABL has a Altman-Z score of 5.76. This is amongst the best in the industry. ABL outperforms 90.91% of its industry peers.
The Debt to FCF ratio of ABL is 1.87, which is an excellent value as it means it would take ABL, only 1.87 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.87, ABL belongs to the top of the industry, outperforming 80.30% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that ABL is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.23, ABL is doing good in the industry, outperforming 68.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Altman-Z | 5.76 |
ROIC/WACC1.18
WACC8.39%
2.3 Liquidity
ABL has a Current Ratio of 1.70. This is a normal value and indicates that ABL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.70, ABL is in line with its industry, outperforming 51.52% of the companies in the same industry.
A Quick Ratio of 1.24 indicates that ABL should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.24, ABL is in line with its industry, outperforming 56.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.40% over the past year.
The Earnings Per Share has been growing slightly by 7.59% on average over the past years.
Looking at the last year, ABL shows a small growth in Revenue. The Revenue has grown by 6.37% in the last year.
The Revenue has been growing slightly by 5.63% on average over the past years.
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
3.2 Future
ABL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.89% yearly.
The Revenue is expected to grow by 7.22% on average over the next years.
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.98 indicates a rather expensive valuation of ABL.
Based on the Price/Earnings ratio, ABL is valued a bit cheaper than the industry average as 63.64% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.38. ABL is around the same levels.
Based on the Price/Forward Earnings ratio of 21.75, the valuation of ABL can be described as rather expensive.
ABL's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.83, ABL is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.98 | ||
| Fwd PE | 21.75 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as ABL.
60.61% of the companies in the same industry are more expensive than ABL, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.35 | ||
| EV/EBITDA | 20.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ABL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.18
PEG (5Y)3.29
EPS Next 2Y10.8%
EPS Next 3Y10.58%
5. Dividend
5.1 Amount
ABL has a Yearly Dividend Yield of 1.91%.
Compared to an average industry Dividend Yield of 1.16, ABL pays a bit more dividend than its industry peers.
ABL's Dividend Yield is comparable with the S&P500 average which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.91% |
5.2 History
The dividend of ABL is nicely growing with an annual growth rate of 11.40%!
Dividend Growth(5Y)11.4%
Div Incr Years6
Div Non Decr Years6
5.3 Sustainability
ABL pays out 28.93% of its income as dividend. This is a sustainable payout ratio.
ABL's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP28.93%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
FRA:ABL (12/19/2025, 7:00:00 PM)
106.42
-1.34 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners81.17%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap185.05B
Revenue(TTM)43.84B
Net Income(TTM)13.98B
Analysts79.43
Price Target124.8 (17.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.91% |
Yearly Dividend1.89
Dividend Growth(5Y)11.4%
DP28.93%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-0.82%
Min EPS beat(2)-1.06%
Max EPS beat(2)-0.58%
EPS beat(4)1
Avg EPS beat(4)-0.52%
Min EPS beat(4)-1.16%
Max EPS beat(4)0.73%
EPS beat(8)3
Avg EPS beat(8)0.07%
EPS beat(12)7
Avg EPS beat(12)1.63%
EPS beat(16)11
Avg EPS beat(16)5.69%
Revenue beat(2)0
Avg Revenue beat(2)-0.81%
Min Revenue beat(2)-1.29%
Max Revenue beat(2)-0.33%
Revenue beat(4)0
Avg Revenue beat(4)-1.08%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)-0.33%
Revenue beat(8)0
Avg Revenue beat(8)-0.75%
Revenue beat(12)4
Avg Revenue beat(12)0.15%
Revenue beat(16)8
Avg Revenue beat(16)1.85%
PT rev (1m)-1.38%
PT rev (3m)1.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.48%
EPS NY rev (1m)0%
EPS NY rev (3m)0.15%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.98 | ||
| Fwd PE | 21.75 | ||
| P/S | 4.95 | ||
| P/FCF | 31.35 | ||
| P/OCF | 23.78 | ||
| P/B | 4.26 | ||
| P/tB | 10.14 | ||
| EV/EBITDA | 20.14 |
EPS(TTM)4.26
EY4%
EPS(NY)4.89
Fwd EY4.6%
FCF(TTM)3.39
FCFY3.19%
OCF(TTM)4.47
OCFY4.2%
SpS21.52
BVpS25
TBVpS10.49
PEG (NY)2.18
PEG (5Y)3.29
Graham Number48.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.6% | ||
| ROE | 27.43% | ||
| ROCE | 11.52% | ||
| ROIC | 9.9% | ||
| ROICexc | 11.13% | ||
| ROICexgc | 21.33% | ||
| OM | 18.29% | ||
| PM (TTM) | 31.88% | ||
| GM | 56.19% | ||
| FCFM | 15.78% |
ROA(3y)11.2%
ROA(5y)9.84%
ROE(3y)20.61%
ROE(5y)19.06%
ROIC(3y)10.45%
ROIC(5y)10.18%
ROICexc(3y)12.18%
ROICexc(5y)11.89%
ROICexgc(3y)32.65%
ROICexgc(5y)35.03%
ROCE(3y)12.16%
ROCE(5y)11.86%
ROICexgc growth 3Y-24.08%
ROICexgc growth 5Y-8.19%
ROICexc growth 3Y-10.71%
ROICexc growth 5Y6.04%
OM growth 3Y-5.79%
OM growth 5Y2.63%
PM growth 3Y24.85%
PM growth 5Y22.55%
GM growth 3Y-0.89%
GM growth 5Y-1.07%
F-Score7
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | 1.87 | ||
| Debt/EBITDA | 1.04 | ||
| Cap/Depr | 70.33% | ||
| Cap/Sales | 5.02% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 81.77% | ||
| Profit Quality | 49.49% | ||
| Current Ratio | 1.7 | ||
| Quick Ratio | 1.24 | ||
| Altman-Z | 5.76 |
F-Score7
WACC8.39%
ROIC/WACC1.18
Cap/Depr(3y)63.63%
Cap/Depr(5y)61.92%
Cap/Sales(3y)4.94%
Cap/Sales(5y)5.1%
Profit Quality(3y)82.78%
Profit Quality(5y)99.6%
High Growth Momentum
Growth
EPS 1Y (TTM)10.4%
EPS 3Y-3.58%
EPS 5Y7.59%
EPS Q2Q%7.44%
EPS Next Y11.44%
EPS Next 2Y10.8%
EPS Next 3Y10.58%
EPS Next 5Y9.89%
Revenue 1Y (TTM)6.37%
Revenue growth 3Y-0.88%
Revenue growth 5Y5.63%
Sales Q2Q%6.9%
Revenue Next Year6.44%
Revenue Next 2Y7.19%
Revenue Next 3Y7.32%
Revenue Next 5Y7.22%
EBIT growth 1Y15.18%
EBIT growth 3Y-6.62%
EBIT growth 5Y8.41%
EBIT Next Year27.08%
EBIT Next 3Y15.42%
EBIT Next 5Y13.66%
FCF growth 1Y53.98%
FCF growth 3Y-9.78%
FCF growth 5Y7.14%
OCF growth 1Y39.24%
OCF growth 3Y-6.69%
OCF growth 5Y6.88%
ABBOTT LABORATORIES / ABL.DE FAQ
What is the fundamental rating for ABL stock?
ChartMill assigns a fundamental rating of 6 / 10 to ABL.DE.
What is the valuation status for ABL stock?
ChartMill assigns a valuation rating of 3 / 10 to ABBOTT LABORATORIES (ABL.DE). This can be considered as Overvalued.
What is the profitability of ABL stock?
ABBOTT LABORATORIES (ABL.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of ABBOTT LABORATORIES (ABL.DE) stock?
The Price/Earnings (PE) ratio for ABBOTT LABORATORIES (ABL.DE) is 24.98 and the Price/Book (PB) ratio is 4.26.
Can you provide the financial health for ABL stock?
The financial health rating of ABBOTT LABORATORIES (ABL.DE) is 7 / 10.